Wells Fargo’s NovoCure NVCR Stock Holding History

Wells Fargo’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Sell	85,000 -85,000	-50%	-$1.29M	﹤0.01%	3940
2026 Q1	$1.85M	Hold	170,000	–	–	﹤0.01%	3331
2025 Q4	$2.2M	Buy	170,000 +120,000	+240%	+$1.54M	﹤0.01%	3354
2025 Q3	$646K	Hold	50,000	–	–	﹤0.01%	4112
2025 Q2	$890K	Hold	50,000	–	–	﹤0.01%	3768
2025 Q1	$891K	Buy	+50,000	New	+$1.14M	﹤0.01%	3719
2020 Q2	–	Sell	-35,800	Closed	-$23K	–	6646
2020 Q1	$23K	Buy	+35,800	New	+$2.83M	﹤0.01%	5567

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wells Fargo's NVCR Position: Q2 2026 in Review

Wells Fargo reduced its NovoCure (NVCR) stake by 14% in Q2 2026, selling an estimated $6.4M and leaving 2,528,093 shares worth $38.3M. The position accounts for 0.01% of the portfolio, ranked #1208.

Wells Fargo first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $197M in Q4 2020. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Wells Fargo held 2,528,093 shares of NovoCure worth $38.3M as of Q2 2026.
Wells Fargo sold 423,144 NovoCure shares in Q2 2026, an estimated $6.4M.
NovoCure made up 0.01% of Wells Fargo's portfolio in Q2 2026, its #1208 holding.
Wells Fargo first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
Wells Fargo's NovoCure position peaked at $197M in Q4 2020.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.